CELESTINA ZENAIDA AGUILAR: Open Payments
NPI 1952033235 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,654 in 117 payments from 21 companies in 2025. Trend: 2023 $2,421 · 2024 $1,752 · 2025 $2,654
Food & beverage: $2,654
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 54 | $1,355 |
| PFIZER INC. | 13 | $224 |
| Otsuka America Pharmaceutical, Inc. | 5 | $201 |
| UCB, Inc. | 6 | $146 |
| Novartis Pharmaceuticals Corporation | 5 | $128 |
| ARGENX US, INC. | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Aucta Pharmaceuticals, Inc. | 8 | $78 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Janssen Biotech, Inc. | 2 | $41 |
Products named: QULIPTA, BOTOX, UBRELVY, NURTEC ODT, REXULTI, Rystiggo, KESIMPTA, VYVGART HYTRULO.
Industry payments across NV — which companies pay providers there.
